Dallas, Texas–(Newsfile Corp. – October 2, 2024) – Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners initiates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL)

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Advancing proprietary, synthetic first and best-in-class cannabinoid and psychedelic-assisted therapeutics
  • Conducting FDA phase 2/3 trial, IHL-42X, for the treatment of Obstructive Sleep Apnea (OSA)
  • IHL-42X pivotal phase 2 top-line data expected first half 2025
Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/225397_figure1.png

Click image above to view full announcement.

About Stonegate

Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.

Original Source